SEARCH

SEARCH BY CITATION

References

  • 1
    Thamm DH, Vail DM. Mast cell tumors. In: Withrow SW, Vail DM, eds. Small Animal Clinical Oncology, 4th ed. St. Louis, MO: Saunders/Elsevier; 2007:402424.
  • 2
    London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:38563865.
  • 3
    Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:13011309.
  • 4
    Downing S, Chien MB, Kass PH, et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002;63:17181723.
  • 5
    Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 2008;6:11371145.
  • 6
    Davies DR, Wyatt KM, Jardine JE, et al. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc 2004;40:124130.
  • 7
    Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 2006;68:581587.
  • 8
    Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor: A retrospective study of 41 cases. J Vet Int Med 1999;13:491497.
  • 9
    Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for treatment of canine mast cell tumours. J Vet Intern Med 2008;22:13901396.
  • 10
    Rassnik KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601605.
  • 11
    Rassnick KM, Bailey DB, Russell DS, et al. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumors. Vet Comp Onc 2010;8:209220.
  • 12
    Vickery KR, Wilson H, Vail DM, Thamm DH. Dose-escalating vinblastine for the treatment of canine mast cell tumors. Vet Comp Oncol 2008;6:111119.
  • 13
    Hutchinson D, Garden C, Hutchinson D, Garden C, eds. 12 Golden GCP Rules for Veterinary Studies. Glasgow, Surrey, UK: Canary Ltd; 2001.
  • 14
    Rowinsky EK. Antimicrotubule agents. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:253267.
  • 15
    Poirier VJ, Hershey AE, Burgess KE, et al. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med 2004;18:219222.
  • 16
    von Euler H, Pivera P, Nyman H, et al. A dose-finding study with a water-soluble formulation of paclitaxel (Paccal® Vet) for the treatment of malignant high grade solid tumors in dogs. Vet Comp Oncol 2011; in press.
  • 17
    VICH GL9. International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products. Available at: http://www.vichsec.org/pdf/2000/Gl09_st7.pdf. Accessed December 16, 2011.
  • 18
    Theilen GH. Performance status score. In: Theilen GH, Madewell BR, eds. Veterinary Cancer Medicine, 2nd ed. Philadelphia, PA: Lea & Febiger; 1987:59.
  • 19
    Rivera P, et al. Efficacy and toxicity of a new formulation of paclitaxel (Paclical® Vet) in a phase I+II study for the treatment of malignant tumours in dogs. Proceedings of the ECVIM-CA Annual Congress, Budapest, Hungary, 2007.
  • 20
    VCOG-CTCAE. Veterinary cooperative oncology group – Common terminology criteria for adverse events following chemotherapy or biologic antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004;2:194213.
  • 21
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST). J Natl Cancer Inst 2000;92:205216.
  • 22
    Patnaik AK. Canine cutaneous mast cell tumor: Morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469474.
  • 23
    Owen LN. TNM Classification of Tumors in Domestic Animals, 1st ed. Geneva: World Health Organization, (vol. 34) 1980.
  • 24
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228247.
  • 25
    VeDDRA. Veterinary dictionary for drug regulatory activities. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094802.pdf. Accessed December 16, 2011.
  • 26
    EMA. Guideline on statistical principles for veterinary clinical trials. 2010. EMA/CVMP/EWP/81976/2010 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500097081.pdf. Accessed December 16, 2011.
  • 27
    Henry CJ, Downing S, Rosenthal RC, et al. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumours in clinically affected dogs. Am J Vet Res 2007;68:12461251.
  • 28
    Rau SE, Barber LG, Burgess KE. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J Vet Intern Med 2010;24:14521457.
  • 29
    Skorupski KA, Hammond GM, Irish AM, et al. Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. J Vet Intern Med 2011;25:838845.
  • 30
    VCOG Consensus Statement. Veterinary cooperative oncology group – Common terminology criteria for adverse events following chemotherapy or biologic antineoplastic therapy in dogs and cats v1.1. Vet Compar Oncol 2011; e-pub ahead of print, 20JUL2011.DOI:10.1111/j.1476-5829.2011.00283.x.